UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 9, 2018

LIGHTBRIDGE CORPORATION

(Exact name of registrant as specified in its charter)

Nevada	001-34487	91-1975651
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

11710 Plaza America Drive, Suite 2000 Reston, VA 20190

(Address of principal executive offices, including zip code)

(571) 730-1200

(Registrant's Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On August 9, 2018 Lightbridge Corporation issued a press release relating to its results for the three months ended June 30, 2018. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in this Current Report on Form 8-K under Item 2.02, including the accompanying press release, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference to such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
<u>99.1</u>	Press Release dated August 9, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LIGHTBRIDGE CORPORATION

By: /s/ Seth Grae
Name: Seth Grae Dated: August 9, 2018

Title: President and Chief Executive Officer



FOR IMMEDIATE RELEASE

Lightbridge Reports Financial Results for the Second Quarter of 2018 and Provides Business Update on Enfission and Other Developments

RESTON, VA, August 9, 2018 -- Lightbridge Corporation (NASDAQ: LTBR), a U.S. nuclear fuel technology company, today provided a business update and reported financial results for the second quarter ended June 30, 2018.

Seth Grae, President & Chief Executive Officer of Lightbridge Corporation, commented, "We are making accelerated progress, along with Enfission, towards validation and commercialization of our metallic nuclear fuel, which significantly enhances the economics and power output of existing and planned nuclear reactors, in addition to the safety and non-proliferation benefits of the fuel. Importantly, we recently announced that we now plan to conduct the initial testing and demonstration of our advanced metallic nuclear fuel in the United States, which will allow us to accelerate our commercial deployment timeline. Specifically, we plan to commence testing of our fuel in a U.S. research reactor by 2020, as well as deploy a lead test rod assembly in a U.S. commercial reactor by 2021. We appreciate the tremendous industry and governmental support, which has made this acceleration possible. We look forward to announcing formal arrangements for irradiation testing of our fuel samples in a U.S. research reactor and our lead test rod assembly program with a U.S. nuclear utility later this year or early next year. The growing support for our fuel was further evidenced by the positive feedback Lightbridge and Enfission received at the World Nuclear Exhibition in June, which is the world's largest industry gathering of its type."

"In June, we were awarded a key patent for our metallic nuclear fuel assembly design in the United States, which further supports our strategy to test and commercialize our fuel in the U.S. We also received notice for a new patent in Japan related to Lightbridge's innovative metallic fuel rod and fuel assembly design. Japan has 39 operable nuclear reactors and, given the fact 9 reactors have been brought back online with a further 16 in the process of restart approval, we expect Lightbridge's fuel will play an important role in Japan's nuclear plant restart efforts."

"Our balance sheet remains strong and we ended the quarter with approximately \$25.7 million of cash and cash equivalents as of June 30, 2018, which does not include \$5.2 million of cash that we have contributed into Enfission, year-to-date. In addition, Framatome has commenced cash contributions into Enfission as well. At the same time, we continue to pursue a variety of non-dilutive funding options, including seeking government grants to accelerate our commercialization timeline. We believe our fuel development program is well suited for these programs, which could be quite meaningful."

ENFISSION R&D ADVANCEMENTS THIS QUARTER

1. Fabrication:

- Completed initial cost estimates for a U.S.-based facility to develop fabrication process and produce partial-length and full-length fuel rods
- Began preparatory work at a lab facility and initial material testing to support fabrication development
- · Completed the following key fabrication process activities:
 - o Developed coextrusion models for process evaluation and optimization
 - o Developed equipment functional specifications
- · Initiated fabrication of samples to select the most optimal alloy forming process

2. Fuel Design:

- · Successfully completed initial modifications of APOLLO-2 neutronics code to model Lightbridge Fuel™ geometry
- · Evaluated and selected the most suitable Critical Heat Flux (CHF) heater rod design for CHF testing
- · Evaluated fuel rod design alternatives to optimize fuel performance
- · Devised and evaluated lead test rod (LTR) design options
- · Assessed alternative options for irradiation testing and identified pathway to maintain deployment schedule

3. Regulatory Licensing:

- · Completed regulatory engagement plan for U.S. NRC interactions
- · Began process to identify fuel design limits in support of licensing activities
- · Completed preparatory work for first NRC meeting to be held in Q3 2018

Balance Sheet Overview

At June 30, 2018, we had cash and cash equivalents of approximately \$25.7 million, as compared to approximately \$4.5 million at December 31, 2017. The \$21.2 million increase in cash and cash equivalents resulted from the sale of approximately \$25.9 million of common stock and net proceeds of \$3.9 million of preferred stock during the six months ended June 30, 2018. This amount of cash inflow was partially offset by net cash used in operating activities of approximately \$3.2 million and our capital contributions for our capital investment in Enfission of approximately \$5.2 million in 2018. We used cash during the six months ended June 30, 2018 primarily to fund our research and development expenses and general and administrative expenses. We had a working capital surplus of approximately \$24.8 million. Stockholders' equity at June 30, 2018 was approximately \$28.7 million compared to stockholders' equity of approximately \$5.8 million at December 31, 2017.

<u> Operating Results – Second Quarter of Fiscal 2018 Compared to Second Quarter of Fiscal 2017</u>

Net losses incurred for the three months ended June 30, 2018 and 2017 amounted to approximately \$3.5 million and \$1.6 million respectively. For the second quarter ended June 30, 2018, total general and administrative expenses increased by \$0.5 million as compared to the three months ended June 30, 2017. The increase was due to an increase in professional fees which was primarily due to the hiring of a consulting firm to assist in preparing the application for a grant from the U.S. Department of Energy. Total research and development expenses for the three-months ended June 30, 2018, as compared to the three months ended June 30, 2017, were substantially the same amounts of \$0.5 million. Total net other operating loss that was generated from our equity investment in our joint venture Enfission was approximately \$1.6 million for the three months ended June 30, 2018. This loss reported by Enfission is primarily attributable to research and development expenditures.

2018 Second Quarter Conference Call

Lightbridge will host a conference call on Friday, August 10th at 11:00 a.m. Eastern Time to discuss the company's financial results for the second quarter ending June 30, 2018, as well as the Company's corporate progress and other meaningful developments.

Interested parties can access the conference call by calling 877-407-0778 for U.S. callers, or +1-201-689-8565 for international callers. The call will be available on the Company's website via webcast at http://ir.ltbridge.com/events.cfm. The conference call will be led by Seth Grae, President and Chief Executive Officer and other Lightbridge executives will also be available to answer questions. Questions may also be submitted in writing before or during the conference call to ir@Ltbridge.com.

A webcast will also be archived on the Company's website and a telephone replay of the call will be available approximately one hour following the call, through 11 p.m. September 10, 2018, and can be accessed by calling: 877-481-4010 (U.S. callers) or +1-919-882-2331 (international callers) and entering conference ID: 36277.

About Lightbridge Corporation

Lightbridge (NASDAQ: LTBR) is a nuclear fuel technology development company based in Reston, Virginia, USA. The Company develops proprietary next generation nuclear fuel technologies for current and future reactors, which significantly enhances the economics and safety of nuclear power, operating about 1000° C cooler than standard fuel. In January 2018, Lightbridge and Framatome, Inc. formed a 50-50 joint venture, Enfission, LLC, to develop, license, manufacture, and sell nuclear fuel assemblies based on Lightbridge-designed metallic fuel technology and other advanced nuclear fuel intellectual property. Enfission has the exclusive rights to this technology and is responsible for the development of manufacturing processes and fuel assembly designs for pressurized water reactors (PWRs), boiling water reactors (BWRs), water-cooled small modular reactors, and water-cooled research reactors developed around this intellectual property. PWRs and BWRs constitute the most widely used reactor types in the world. Four large electric utilities that generate about half the nuclear power in the US already advise Lightbridge on fuel development and deployment. In addition to distributions from Enfission based on the parties' ownership interest in the joint venture, Lightbridge anticipates receiving future licensing revenues in connection with sales by Enfission of nuclear fuel incorporating its intellectual property. Lightbridge also provides comprehensive advisory services for established and emerging nuclear programs based on a philosophy of transparency, non-proliferation, safety and operational excellence. For more information please visit: www.ltbridge.com.

To receive Lightbridge Corporation updates via e-mail, subscribe at http://ir.ltbridge.com/alerts.cfm .

Lightbridge is on Twitter. Sign up to follow @LightbridgeCorp at http://twitter.com/lightbridgecorp.

Forward Looking Statements

With the exception of historical matters, the matters discussed in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's competitive position, the timing of demonstration testing and commercial production, the Company's entry into agreements with nuclear fuel manufacturers and the timing thereof, the potential impact of the U.S. Clean Power Plan and similar regulations, the Company's anticipated financial resources and position, the Company's product and service offerings. These statements are based on current expectations on the date of this news release and involve a number of risks and uncertainties that may cause actual results to differ significantly from such estimates. The risks include, but are not limited to, the degree of market adoption of the Company's product and service offerings; market competition; dependence on strategic partners; demand for fuel for nuclear reactors; the Company's ability to manage its business effectively in a rapidly evolving market; as well as other factors described in Lightbridge's filings with the Securities and Exchange Commission. Lightbridge does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements.

Investor Relations Contact:

David Waldman/Natalya Rudman Tel. +1 855-379-9900 ir@ltbridge.com

*** tables follow ***

Lightbridge Corporation Condensed Consolidated Balance Sheets

		June 30, 2018		December 31, 2017	
	(Unaudited)	_		
ASSETS					
Current Assets					
Cash and cash equivalents	\$	25,707,368	\$	4,515,398	
Accounts receivable - project revenue and reimbursable project costs		-		10,400	
Other receivable from joint venture		414,957		-	
Prepaid expenses and other current assets		107,861		70,067	
Deferred financing costs, net		<u> </u>		491,168	
Total Current Assets	_	26,230,186		5,087,033	
Investment in joint venture		2,415,228		<u>-</u>	
Other Assets					
Patent costs		1,506,672		1,367,692	
Deferred financing costs, net		<u>-</u>		491,268	
Total Other Assets		1,506,672		1,858,960	
Total Assets	\$	30,152,086	\$	6,945,993	
LIABILITIES AND STOCKHOLDERS' EQUITY					
Current Liabilities	•		•		
Accounts payable and accrued liabilities	\$	1,405,341	\$	1,151,210	
Total Current Liabilities		1 405 241			
	_	1,405,341		1,151,210	
Total Liabilities	_	1,405,341		1,151,210	
			_ _		
Commitments and Contingencies – Note 5					
Commitments and Contingencies – Note 5 Stockholders' Equity					
Commitments and Contingencies – Note 5 Stockholders' Equity Preferred stock, \$0.001 par value, 10,000,000 authorized shares:					
Commitments and Contingencies – Note 5 Stockholders' Equity Preferred stock, \$0.001 par value, 10,000,000 authorized shares: Convertible Series A preferred shares, 908,740 shares and 1,020,000 shares issued and outstanding at June 30					
Commitments and Contingencies – Note 5 Stockholders' Equity Preferred stock, \$0.001 par value, 10,000,000 authorized shares: Convertible Series A preferred shares, 908,740 shares and 1,020,000 shares issued and outstanding at June 30 2018 and December 31, 2017, respectively (liquidation preference \$2,849,000 and \$3,088,764 at June 30, 2018)					
Commitments and Contingencies – Note 5 Stockholders' Equity Preferred stock, \$0.001 par value, 10,000,000 authorized shares: Convertible Series A preferred shares, 908,740 shares and 1,020,000 shares issued and outstanding at June 30 2018 and December 31, 2017, respectively (liquidation preference \$2,849,000 and \$3,088,764 at June 30, 2018 and December 31, 2017, respectively)		1,405,341		1,151,210	
Commitments and Contingencies – Note 5 Stockholders' Equity Preferred stock, \$0.001 par value, 10,000,000 authorized shares: Convertible Series A preferred shares, 908,740 shares and 1,020,000 shares issued and outstanding at June 30 2018 and December 31, 2017, respectively (liquidation preference \$2,849,000 and \$3,088,764 at June 30, 2018)		1,405,341		1,151,210	
Commitments and Contingencies – Note 5 Stockholders' Equity Preferred stock, \$0.001 par value, 10,000,000 authorized shares: Convertible Series A preferred shares, 908,740 shares and 1,020,000 shares issued and outstanding at June 30 2018 and December 31, 2017, respectively (liquidation preference \$2,849,000 and \$3,088,764 at June 30, 2018 and December 31, 2017, respectively) Convertible Series B preferred shares, 2,666,667 and 0 shares issued and outstanding at June 30, 2018 and		1,405,341		1,151,210	
Commitments and Contingencies – Note 5 Stockholders' Equity Preferred stock, \$0.001 par value, 10,000,000 authorized shares: Convertible Series A preferred shares, 908,740 shares and 1,020,000 shares issued and outstanding at June 30 2018 and December 31, 2017, respectively (liquidation preference \$2,849,000 and \$3,088,764 at June 30, 2018 and December 31, 2017, respectively) Convertible Series B preferred shares, 2,666,667 and 0 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively (liquidation preference \$4,116,667 at June 30, 2018)		1,405,341		1,151,210	
Commitments and Contingencies – Note 5 Stockholders' Equity Preferred stock, \$0.001 par value, 10,000,000 authorized shares: Convertible Series A preferred shares, 908,740 shares and 1,020,000 shares issued and outstanding at June 30 2018 and December 31, 2017, respectively (liquidation preference \$2,849,000 and \$3,088,764 at June 30, 2018 and December 31, 2017, respectively) Convertible Series B preferred shares, 2,666,667 and 0 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively (liquidation preference \$4,116,667 at June 30, 2018) Common stock, \$0.001 par value, 100,000,000 authorized, 28,621,758 shares and 12,737,703 shares issued and		909		1,020	
Commitments and Contingencies – Note 5 Stockholders' Equity Preferred stock, \$0.001 par value, 10,000,000 authorized shares: Convertible Series A preferred shares, 908,740 shares and 1,020,000 shares issued and outstanding at June 30 2018 and December 31, 2017, respectively (liquidation preference \$2,849,000 and \$3,088,764 at June 30, 2018 and December 31, 2017, respectively) Convertible Series B preferred shares, 2,666,667 and 0 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively (liquidation preference \$4,116,667 at June 30, 2018) Common stock, \$0.001 par value, 100,000,000 authorized, 28,621,758 shares and 12,737,703 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively		909 2,667 28,622		1,020 1,020 12,738 93,602,539	
Commitments and Contingencies – Note 5 Stockholders' Equity Preferred stock, \$0.001 par value, 10,000,000 authorized shares: Convertible Series A preferred shares, 908,740 shares and 1,020,000 shares issued and outstanding at June 30 2018 and December 31, 2017, respectively (liquidation preference \$2,849,000 and \$3,088,764 at June 30, 2018 and December 31, 2017, respectively) Convertible Series B preferred shares, 2,666,667 and 0 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively (liquidation preference \$4,116,667 at June 30, 2018) Common stock, \$0.001 par value, 100,000,000 authorized, 28,621,758 shares and 12,737,703 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively Additional paid-in capital		909 2,667 28,622 124,774,561		1,151,210	

Lightbridge Corporation Unaudited Condensed Consolidated Statements of Operations

		Three Months Ended June 30,				Six Months Ended June 30,			
		2018		2017		2018		2017	
Revenue									
Consulting Revenue	\$	-	\$	14,425	\$	-	\$	149,910	
Cost of Consulting Services Provided	_	_	_	4,300	_			89,663	
Gross Margin		<u>-</u>	_	10,125	_	<u>-</u>	_	60,247	
Operating Expenses									
General and administrative		1,453,030		971,290		3,676,620		2,179,592	
Research and development		538,031		545,644		1,449,065		1,009,987	
Total Operating Expenses		1,991,061		1,516,934		5,125,685		3,189,579	
Other Operating Income and (Loss)		107.021				507.274			
Other income from joint venture		187,031		-		587,374		-	
Equity in loss from joint venture		(1,773,445)	_	<u> </u>	_	(2,801,772)	_		
Total Other Operating Income and (Loss)		(1,586,414)	_	-	_	(2,214,398)	_		
Operating Loss	_	(3,577,475)	-	(1,506,809)	_	(7,340,083)	_	(3,129,332)	
Other Income and (Expenses)									
Interest income		60,462		-		84,019		-	
Financing costs		-		(130,877)		(982,436)		(253,681)	
Other income		-		23				47	
Total Other Income and (Expenses)		60,462		(130,854)		(898,417)		(253,634)	
		(2.517.012)		(1 (27 ((2)		(0.220.500)		(2.202.0(0)	
Loss before income taxes		(3,517,013)		(1,637,663)		(8,238,500)		(3,382,966)	
Income taxes	Φ.	(2.517.012)	Φ.	(1.627.662)	Φ.	(0.220.500)	Ф	(2.202.066)	
Net loss	\$	(3,517,013)	\$	(1,637,663)	\$	(8,238,500)	\$	(3,382,966)	
Accumulated preferred stock dividend		(119,000)		(49,000)		(214,667)		(98,000)	
Deemed additional dividend on preferred stock dividend due the beneficial									
conversion feature		(49,373)		-		(85,680)		-	
Deemed dividend on issuance on Series B convertible preferred stock due to									
beneficial conversion feature		<u> </u>		<u>-</u>		(2,624,836)			
Net loss attributable to common stockholders		(3,685,386)		(1,686,663)		(11,163,683)		(3,480,966)	
Net Loss Per Common Share, Basic and Diluted	\$	(0.14)	\$	(0.17)	\$	(0.50)	\$	(0.37)	
Weighted Average Number of Common Shares Outstanding		25,702,352		9,911,864		22,484,840		9,524,939	

Lightbridge Corporation Unaudited Condensed Consolidated Statements of Cash Flows

Operating Activities: 2018 Net Loss \$ (8,238,500) \$ Adjustments to reconcile net loss from operations to net cash used in operating activities: 3 (4,21,745) Stock-based compensation 982,436 Equity in loss from joint venture 2,801,772 Changes in operating working capital tiems: 10,400 Changes in operating working capital tiems: (10,400) Other receivable from joint venture (414,957) Other receivable from joint venture (37,749) Accounts payable and accrued liabilities 254,131 Deferred lease abandonment liability (3,220,767) Net Cash Used In Operating Activities (3,220,767) Investing Activities: (5,217,000) Patent costs (5,355,980) Net Cash Used In Investing Activities (5,355,980) Financing Activities: (5,355,980) Net proceeds from the issuance of perferted stock 3,900,001 Restricted cash 22,868,716 Net proceeds from the issuance of preferted stock 3,900,001 Restricted cash 22,9768,717 Cash and Cash Equivalents 22,9768,	Ended
Net Loss \$ (8,238,500) \$ Adjustments to reconcile net loss from operations to net cash used in operating activities: 1,421,745 Stock-based compensation 982,436 Equity in loss from joint venture 2,801,772 Changes in operating working capital items: 10,400 Accounts receivable - fees and reimbursable project costs 10,400 Other receivable from joint venture (414,957) Prepaid expenses and other assets (3,794) Accounts payable and accrued liabilities 254,131 Deferred lease abandonment liability - Net Cash Used In Operating Activities (3,220,767) Investing Activities: (138,980) Investing Activities: (5,217,000) Patent costs (3,355,980) Net Cash Used In Investing Activities (5,355,980) Financing Activities: - Net proceeds from the issuance of common stock 25,868,716 Net proceeds from the issuance of preferred stock 3,900,001 Restricted cash - Net Cash Provided by Financing Activities 21,191,970 Cash and Cash Equivalents 21,	2017
Adjustments to reconcile net loss from operations to net cash used in operating activities: Stock-based compensation Amortization of deferred financing cost Age, 2436 Equity in loss from joint venture Changes in operating working capital items: Accounts receivable - fees and reimbursable project costs Other receivable from joint venture (414,957) Prepaid expenses and other assets Accounts payable and accrued liabilities 254,131 Deferred lease abandonment liability Net Cash Used In Operating Activities Investing Activities: Investing Activities: Investment in joint venture Net Cash Used In Investing Activities Stock of the description of the service of the	
Stock-based compensation 1,421,745 Amortization of deferred financing cost 982,436 Equity in loss from joint venture 2,801,772 Changes in operating working capital items: 10,400 Other receivable - fees and reimbursable project costs 10,400 Other receivable from joint venture (414,957) Prepaid expenses and other assets (37,794) Accounts payable and accrued liabilities 254,131 Deferred lease abandonment liability - Net Cash Used In Operating Activities (3,220,767) Investing Activities: - Investing Activities (138,980) Net Cash Used In Investing Activities (5,217,000) Patent costs (138,980) Net Cash Used In Investing Activities 25,868,716 Net proceeds from the issuance of common stock 25,868,716 Net proceeds from the issuance of preferred stock 3,900,001 Restricted cash - Net Cash Provided by Financing Activities 29,768,717 Net Increase In Cash and Cash Equivalents 21,191,970 Cash and Cash Equivalents, Beginning of Period 4,515,398 <td>(3,382,966)</td>	(3,382,966)
Amortization of deferred financing cost 982,436 Equity in loss from joint venture 2,801,772 Changes in operating working capital items: 10,400 Other receivable - fees and reimbursable project costs 10,400 Other receivable from joint venture (414,957) Prepaid expenses and other assets (37,794) Accounts payable and accrued liabilities 254,131 Deferred lease abandonment liability - Net Cash Used In Operating Activities (3,220,767) Investing Activities: (138,980) Investing Activities (138,980) Net Cash Used In Investing Activities (138,980) Net Cash Used In Investing Activities 25,868,716 Net proceeds from the issuance of common stock 25,868,716 Net proceeds from the issuance of preferred stock 3,900,001 Restricted cash - Net Cash Provided by Financing Activities 29,768,717 Net Increase In Cash and Cash Equivalents 21,191,970 Cash and Cash Equivalents, Beginning of Period 4,515,398 Cash and Cash Equivalents, End of Period \$25,707,368 Supplemental Disclo	
Equity in loss from joint venture 2,801,772 Changes in operating working capital items: 10,400 Other receivable - fees and reimbursable project costs 10,400 Other receivable from joint venture (414,957) Prepaid expenses and other assets (37,794) Accounts payable and accrued liabilities 254,131 Deferred lease abandonment liability - Net Cash Used In Operating Activities (3,220,767) Investing Activities: (138,980) Investing Activities: (138,980) Net Cash Used In Investing Activities (5,355,980) Financing Activities: 25,868,716 Net proceeds from the issuance of common stock 25,868,716 Net proceeds from the issuance of preferred stock 3,900,001 Restricted cash - Net Cash Provided by Financing Activities 29,768,717 Net Increase In Cash and Cash Equivalents 21,191,970 Cash and Cash Equivalents, Beginning of Period 4,515,398 Cash and Cash Equivalents, End of Period \$25,707,368 Supplemental Disclosure of Cash Flow Information: Cash apid during the period: I	427,880
Changes in operating working capital items: 10,400 Accounts receivable - fees and reimbursable project costs 10,405 Other receivable from joint venture (414,957) Prepaid expenses and other assets (37,794) Accounts payable and accrued liabilities 254,131 Deferred lease abandonment liability - Net Cash Used In Operating Activities (3,220,767) Investing Activities: (138,980) Investing Activities: (138,980) Net Cash Used In Investing Activities (5,355,980) Financing Activities: 25,868,716 Net proceeds from the issuance of common stock 25,868,716 Net proceeds from the issuance of preferred stock 3,900,001 Restricted cash - Net Cash Provided by Financing Activities 29,768,717 Net Increase In Cash and Cash Equivalents 21,191,970 Cash and Cash Equivalents, Beginning of Period 3,25,707,368 Supplemental Disclosure of Cash Flow Information: Cash apaid during the period: Interest paid 8	245,609
Accounts receivable - fees and reimbursable project costs 10,400 Other receivable from joint venture (414,957) Prepaid expenses and other assets (37,794) Accounts payable and accrued liabilities 254,131 Deferred lease abandonment liability - Net Cash Used In Operating Activities (3,220,767) Investing Activities: (138,980) Patent costs (138,980) Net Cash Used In Investing Activities (5,355,980) Financing Activities: (3,320,767) Net proceeds from the issuance of common stock 25,868,716 Net proceeds from the issuance of preferred stock 3,900,001 Restricted cash - Net Cash Provided by Financing Activities 29,768,717 Net Increase In Cash and Cash Equivalents 21,191,970 Cash and Cash Equivalents, Beginning of Period 4,515,398 Cash and Cash Equivalents, End of Period \$25,707,368 Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid \$ -	-
Other receivable from joint venture (414,957) Prepaid expenses and other assets (37,794) Accounts payable and accrued liabilities 254,131 Deferred lease abandonment liability - Net Cash Used In Operating Activities (3,220,767) Investing Activities: (138,980) Patent costs (138,980) Net Cash Used In Investing Activities (5,355,980) Financing Activities: 25,868,716 Net proceeds from the issuance of common stock 25,868,716 Net proceeds from the issuance of preferred stock 3,900,001 Restricted cash - Net Cash Provided by Financing Activities 29,768,717 Net Increase In Cash and Cash Equivalents 21,191,970 Cash and Cash Equivalents, Beginning of Period 4,515,398 Cash and Cash Equivalents, End of Period \$ 25,707,368 Supplemental Disclosure of Cash Flow Information: Cash apaid during the period: Interest paid \$ -	
Prepaid expenses and other assets (37,794) Accounts payable and accrued liabilities 254,131 Deferred lease abandonment liability - Net Cash Used In Operating Activities (3,220,767) Investing Activities: (5,217,000) Patent costs (138,980) Net Cash Used In Investing Activities (5,355,980) Financing Activities: 25,868,716 Net proceeds from the issuance of common stock 25,868,716 Net proceeds from the issuance of preferred stock 3,900,001 Restricted cash - Net Cash Provided by Financing Activities 29,768,717 Net Increase In Cash and Cash Equivalents 21,191,970 Cash and Cash Equivalents, Beginning of Period 4,515,398 Cash and Cash Equivalents, End of Period \$ 25,707,368 Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid \$ -	377,545
Accounts payable and accrued liabilities 254,131 Deferred lease abandonment liability - Net Cash Used In Operating Activities (3,220,767) Investing Activities: - Investment in joint venture (5,217,000) Patent costs (138,980) Net Cash Used In Investing Activities (5,355,980) Financing Activities: 25,868,716 Net proceeds from the issuance of common stock 25,868,716 Net proceeds from the issuance of preferred stock 3,900,001 Restricted cash - Net Cash Provided by Financing Activities 29,768,717 Net Increase In Cash and Cash Equivalents 21,191,970 Cash and Cash Equivalents, Beginning of Period 4,515,398 Cash and Cash Equivalents, End of Period \$25,707,368 Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid \$	-
Deferred lease abandonment liability	(50,384)
Net Cash Used In Operating Activities: Investing Activities: Investment in joint venture (5,217,000) Patent costs (138,980) Net Cash Used In Investing Activities (5,355,980) Financing Activities: Net proceeds from the issuance of common stock (25,868,716) Net proceeds from the issuance of preferred stock (3,900,001) Restricted cash (29,768,717) Net Cash Provided by Financing Activities (29,768,717) Net Increase In Cash and Cash Equivalents (21,191,970) Cash and Cash Equivalents, Beginning of Period (3,220,767) Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid (3,220,767) Interest paid ((48,540)
Investing Activities: Investment in joint venture Patent costs Net Cash Used In Investing Activities Financing Activities: Net proceeds from the issuance of common stock Net proceeds from the issuance of preferred stock Restricted cash Net Cash Provided by Financing Activities Net Increase In Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid	(72,186)
Investing Activities: Investment in joint venture Patent costs Net Cash Used In Investing Activities Financing Activities: Net proceeds from the issuance of common stock Net proceeds from the issuance of preferred stock Net proceeds from the issuance of preferred stock Net proceeds from the issuance of preferred stock Net Cash Provided by Financing Activities Net Cash Provided by Financing Activities Net Increase In Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid Supplemental Supplementa	(2,503,042)
Investment in joint venture (5,217,000) Patent costs (138,980) Net Cash Used In Investing Activities (5,355,980) Financing Activities: Net proceeds from the issuance of common stock Net proceeds from the issuance of preferred stock Activities (1,390,001) Restricted cash (1,297,000) Restricted cash (1,297,000) Net Cash Provided by Financing Activities (1,297,000) Patent Cash Provided by Financing Activities (1,297,000) Cash and Cash Equivalents (1,297,000) Cash and Cash Equivalents, Beginning of Period (1,297,000) Cash and Cash Equivalents, End of Period (1,297,000) Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid (1,297,000) Interest paid (1,297,000) Interest paid (1	
Investment in joint venture (5,217,000) Patent costs (138,980) Net Cash Used In Investing Activities (5,355,980) Financing Activities: Net proceeds from the issuance of common stock Net proceeds from the issuance of preferred stock Astricted cash Sestricted cash Sestricted cash Sestricted by Financing Activities (29,768,717) Net Cash Provided by Financing Activities (29,768,717) Net Increase In Cash and Cash Equivalents (21,191,970) Cash and Cash Equivalents, Beginning of Period (32,5707,368) Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid (5,217,000) Interest paid (138,980) Cis, 21,200 Cis, 22,200 Cis, 22,2	
Patent costs Net Cash Used In Investing Activities Financing Activities: Net proceeds from the issuance of common stock Net proceeds from the issuance of preferred stock Net proceeds from the issuance of preferred stock Net proceeds from the issuance of preferred stock Restricted cash Net Cash Provided by Financing Activities Net Increase In Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid Supplemental Supplem	_
Net Cash Used In Investing Activities (5,355,980) Financing Activities: Net proceeds from the issuance of common stock Net proceeds from the issuance of preferred stock Net proceeds from the issuance of preferred stock Restricted cash Net Cash Provided by Financing Activities Net Increase In Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid	(115,172)
Financing Activities: Net proceeds from the issuance of common stock Net proceeds from the issuance of preferred stock Net proceeds from the issuance of preferred stock Restricted cash Net Cash Provided by Financing Activities 29,768,717 Net Increase In Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period 4,515,398 Cash and Cash Equivalents, End of Period \$25,707,368 \$ Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid \$\$	(115,172)
Net proceeds from the issuance of common stock Net proceeds from the issuance of preferred stock Restricted cash Net Cash Provided by Financing Activities Net Increase In Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid 25,868,716 3,900,001 29,768,717 21,191,970 21,191,970 21,191,970 22,707,368 3	(110,172)
Net proceeds from the issuance of common stock Net proceeds from the issuance of preferred stock Restricted cash Net Cash Provided by Financing Activities Net Increase In Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid 25,868,716 3,900,001 29,768,717 21,191,970 21,191,970 21,191,970 22,707,368 3	
Net proceeds from the issuance of preferred stock Restricted cash Net Cash Provided by Financing Activities Net Increase In Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid 3,900,001 29,768,717 29,768,717 21,191,970 4,515,398 Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid	3,025,544
Restricted cash Net Cash Provided by Financing Activities Net Increase In Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid	-
Net Cash Provided by Financing Activities 29,768,717 Net Increase In Cash and Cash Equivalents 21,191,970 Cash and Cash Equivalents, Beginning of Period 4,515,398 Cash and Cash Equivalents, End of Period \$25,707,368 \$ Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid \$\$	(47)
Net Increase In Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period 4,515,398 Cash and Cash Equivalents, End of Period \$ 25,707,368 \$ Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid \$ \$	3,025,497
Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Supplemental Disclosure of Cash Flow Information:	3,023,777
Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid A,515,398 \$ Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid	407,283
Cash and Cash Equivalents, End of Period \$ 25,707,368 \$ Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid \$ - \$	407,203
Cash and Cash Equivalents, End of Period \$ 25,707,368 \$ Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid \$ - \$	3,584,877
Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid \$ - \$	3,364,677
Supplemental Disclosure of Cash Flow Information: Cash paid during the period: Interest paid \$ - \$	3,992,160
Cash paid during the period: Interest paid \$ \$	3,992,100
Cash paid during the period: Interest paid \$ \$	
Interest paid § - §	
Income taxes naid	<u> </u>
meonic taxes paid	<u> </u>
Non-Cash Financing Activity:	
Deemed dividend on issuance Series B convertible preferred stock due to beneficial conversion feature \$ 2,624,836 \$	-
Accumulated preferred stock dividend \$ 214,667 \$	98,000
Decrease in accrued liabilities - stock-based compensation \$ - \$	121,720
Decrease in accrued natifices - stock-based compensation 5 - 5	121,720